APP and Alzheimer disease: ACY-738 administration improved axonal transport, reduced hyperphosphorylated tau and improved performance in contextual fear conditioning, and open field performance in the APP/PS1 murine model of Alzheimer's disease [20] and improved short-term memory in an in vivo multiple sclerosis model [24].